NCT06154967View on ClinicalTrials.gov

To Explore the Effect of Immune-induced Stereotactic Body Radiotherapy (SBRT) on Reversing Immunoresistance in Stage IIIc/IV Non-small Cell Lung Cancer (NSCLC)

NANot yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions
Non-Small Cell Lung Cancer Without Mutation in Epidermal Growth Factor Receptor (Disorder)
Interventions
RADIATION

tereotactic body radiotherapy

In second-line and later treatment, the treatment regimen of SBRT combined with tislelizumab is used

All Listed Sponsors
lead

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

OTHER

NCT06154967 - To Explore the Effect of Immune-induced Stereotactic Body Radiotherapy (SBRT) on Reversing Immunoresistance in Stage IIIc/IV Non-small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter